

References

1. Leung et al. 2014; Am J Gastroenterol. 109(6):855-63
2. Horimatsu et al. 2015; Int J Colorectal Dis. 30(7):947-54.
3. Qumseya et al. 2013; ClinGastroenterolHepatol.11(12):1562-70.e1-2
4. Kaminski et al. 2014; Endoscopy 46(5):435-49
5. ASGE Standards of Practice Committee et al. 2015; GastrointestEndosc. 81(3):502.e1-502.e16
6. ASGE Technology Committee et al. Gastrointest Endosc. 2016 Apr;83(4):684-698.e7.
7. Singh et al. 2013; Dig Endosc. 25 Suppl 2:16-20
8. Kaltenbach et al. 2014; Gut 64(10):1569-77
9. Cuesta et al. 2014; Scand J Gastroenterol. 49(3):355-61
10. Mark-Christensen et al. 2014; Endoscopy 47(3):251-61
11. Holme et al. 2011; GastrointestEndosc. 73(6):1215-22
12. Töx et al. 2013; Endoscopy; 45(6):439-44
13. Garborg et al. 2012; Endoscopy; 44(8):740-6.
14. Sharma et al. 2013; Gut 62 (1):15-21.
15. Hassan et al. 2010, Clin Gastroenterol Hepatol.; 8(10):865-9, 869.e1-3
16. Othman et al. Endoscopy 2009 Jan;41(1):17-24.

Abbreviations

1. ADR: Adenoma detection rate
2. NBI: Narrow Band Imaging
3. DISCARD: Detect Inspect Characterise Resect and Discard
4. ESGE: European Society of Gastrointestinal Endoscopy
5. ASGE: American Society for Gastrointestinal Endoscopy
6. NICE: NBI International Colorectal Endoscopic (classification)

IMAGINE... TOMORROW IS NOW


Be Ready Today with EVIS EXERA III




➤ Explore the evidence at: www.olympus-proven.com.au

Design and content created by Olympus Europa SE & Co. KG.
Specifications, design, and accessories are subject to change without any notice or obligation on the part of the manufacturer.


EVIS EXERA III BENEFITS TODAY




- Up to 14% higher ADR with NBI ⁽¹⁾
- Up to 29% more colorectal polyps found with NBI ⁽²⁾
- Easier monitoring of ADR with NBI optical diagnosis
- 34% more neoplasia found in Barrett's Oesophagus with NBI ⁽³⁾




- Optical diagnosis and DISCARD in the colon with NBI, endorsed by ESGE and ASGE ^(4,5)
- Targeted biopsy in Barrett's Oesophagus surveillance with NBI, endorsed by ASGE ⁽⁶⁾
- Up to 86% fewer biopsies in Barrett's surveillance with NBI and Dual Focus ⁽⁷⁾
- Up to 12% higher diagnostic confidence with Dual Focus ⁽⁸⁾



- Easier insertion and operation for doctors and nurses ⁽⁹⁾
- 4% higher caecal intubation rates ⁽¹⁰⁾
- Easier and more successful intubation for trainees ⁽¹¹⁾
- 18% less sedation ⁽¹²⁾



- Less pain during colonoscopy ⁽¹³⁾
- **78%** of patients experiencing no pain at all ⁽¹³⁾
- High patient comfort and satisfaction



- 20% shorter time to caecum ⁽⁹⁾
- Less sedation ⁽¹²⁾ = lower spending on sedative drugs
- Less sedation ⁽¹²⁾ = quicker patient recovery and less blockage of recovery room
- Lower spending on histopathology (if DISCARD and targeted biopsies are applied) ^(14,15)

VALUE OF EVIS EXERA III FOR HEALTH CARE AND PROCUREMENT

Clinical Outcomes and Secondary Benefits		Clinical Quality	Cost-Effectiveness
NBI	Improves detection ^(1,2)	✓	
	Allows optical diagnosis in the colon (DISCARD) ^(4,5)	✓	✓
	Allows targeted biopsy in Barrett's Oesophagus ^(3,6)	✓	✓
	Allows easy monitoring of ADR	✓	
	Lower spending on histopathology (if DISCARD and targeted biopsies are applied) ^(14,15)		✓
Dual Focus	Increases confidence of optical diagnosis ⁽⁸⁾	✓	
	Less spending on for histopathology (if DISCARD and targeted biopsies are applied) ^(14,15)		✓
RIT	Easier insertion in colonoscopy ⁽⁹⁾	✓	
	High caecal intubation rate with variable stiffness ⁽¹⁶⁾	✓	
	Shorter time to caecum ⁽⁹⁾		✓
	Less sedation → quicker patient recovery ⁽¹²⁾		✓
ScopeGuide	Less patient pain ⁽¹³⁾	✓	
	Higher caecal intubation rate (trainees and experienced clinicians) ⁽¹⁰⁾	✓	
	Shorter time to caecum ⁽¹⁰⁾		✓
	Less sedation → quicker patient recovery ⁽¹⁰⁾		✓
	Less patient pain ⁽¹⁰⁾	✓	